98%
921
2 minutes
20
Because of the bidirectional relationship between atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), individuals with either condition require consideration of screening for the other. In this review, we summarize current evidence and rationale for screening for occult HFpEF in adults with clinical AF; and occult AF in patients with clinically recognized HFpEF. Assessment of pretest probability for occult HFpEF in symptomatic AF patients may help guide additional testing such as exercise right heart catheterization to diagnose HFpEF and guide HFpEF-specific therapies. In patients with HFpEF, AF screening will identify cases of occult AF where anticoagulation may decrease stroke risk, and correlation of previously unknown AF episodes with paroxysmal symptoms may prompt consideration for rhythm control. Therefore, screening may help clinicians understand the etiology of the often-overlapping symptoms, and it may help guide treatments to slow progression of both conditions and their complications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jchf.2024.04.010 | DOI Listing |
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Europace
September 2025
Department of Cardiovascular Medicine, Institute of Science Tokyo, Tokyo, Japan.
J Cardiovasc Electrophysiol
September 2025
Northwell Cardiovascular Institute, Center for Arrhythmias, New Hyde Park, New York, USA.
Background: Atrial fibrillation (AF) and heart failure (HF) frequently coexist in patients, with the development of AF often preceding HF decompensation. We sought to evaluate whether daily remote monitoring of ICD parameters could predict AF occurrence using machine learning techniques in a real-world cohort.
Methods: Data from patients with primary prevention ICDs transmitted daily to the Northwell centralized remote monitoring center between 2012 and 2021 were extracted.
Am J Med Sci
September 2025
The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel; Department of Internal Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.
Objective: Multifocal atrial tachycardia (MAT), characterized by an irregularly irregular rhythm, is often regarded as a clinical imitator of atrial fibrillation (AF). We aimed to evaluate the prevalence of MAT misclassification as AF in the emergency department (ED) setting.
Methods: A retrospective analysis of 1,828 ECGs from patients discharged with AF diagnoses over five years.
Environ Res
September 2025
Department of Environmental Health, Harvard TH Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Background: Fine particulate matter (PM) has been previously linked to cardiovascular diseases (CVDs). PM is a mixture of components, each of which has its own toxicity profile which are not yet well understood. This study explores the relationship between long-term exposure to PM components and hospital admissions with CVDs in the Medicare population.
View Article and Find Full Text PDF